Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associated acute kidney injury
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210428005922/en/
Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN), today announced completion of enrollment for Angion s AKI-002-15 study, a phase-II trial of ANG-3777 in patients at risk of cardiac-surgery associated acute kidney injury (CSA-AKI). This indication is part of the ANG-3777 license agreement both parties signed in November 2020. CSA-AKI is a frequent complication of cardiac bypass surgery seen in about one third of patients and is associated with prolonged hospitalization, progressive kidney failure, and an increased risk of death, commented Dr. John Neylan, Angion s Senior Vice President and Chief Medical Officer. Currently, there are no approved therapies to prevent this serious condition. Thi
About PolyPeptide Group
PolyPeptide is a Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products. Dating back to 1952, PolyPeptide today manufactures around one-half of all currently approved peptide drug substances with a global footprint of six GMP-certified facilities in Europe, the U.S. and India. As a multinational company with more than 900 employees, its diversity brings breadth, depth of knowledge and experience to the group. PolyPeptide has grown organically and by selective acquisition of existing expertise, culminating in its position today as a leader in outsourced peptide manufacturing. PolyPeptide s shares (SIX: PPGN) are listed on the Swiss Stock Exchange. For more information, visit polypeptide.com.
International PolyPeptide Group Chooses SIX For Its IPO Date
29/04/2021
Today, PolyPeptide Group AG (Ticker PPGN ), a global leader in peptide development and manufacturing, listed its shares on the Swiss Stock Exchange. The opening price was CHF 72.50 per share, resulting in a market capitalization of CHF 2.4 billion.
With PolyPeptide Group, SIX welcomes another company from the life sciences sector, further expanding its strong peer group and strengthening its position as Europe’s leading exchange for life sciences companies.
The issued share capital of PolyPeptide comprises of 33,125,001 registered shares, whereas 3,125,000 newly issued registered shares together with existing 8,396,740 registered shares were offered in the IPO. At an issue price of CHF 64.00 per registered share, the placement volume was CHF 737 million (excluding over-allotment option). In addition, the selling shareholder has granted an overallotment option of up to 1,728,261 existing shares.
Ethereum Closing In on $2,800 As ETH 2.0 Deposit Contract Hit New ATH
Reading Time: 2 mins read
On Thursday, the world’s second largest cryptocurrency by market cap, Ethereum surged in an indomitable bull rally. At press time, the coin was trading at a new all-time high of $2,760, a 2.89% gain in the last 24 hours. ETH currently has a market cap of $320 billion.
Asset Manager WisdomTree Lists Ethereum ETP
The price surge comes after one of the world’s biggest asset managers WisdomTree listed its new Ethereum ETP on Deutsche Borse’s Xetra market in Frankfurt and the Swiss Stock Exchange in Zurich.
Angion and Vifor Pharma Announce Completion of Enrollment in Phase 2 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.